The U.S. Food and Drug Administration approved Imaavy (nipocalimab-aahu) on April 29, 2025, according to the agency’s biologics application record. The approval was recorded under biologics license application BLA 761430 and identified the product as a new molecular entity.
Background
Nipocalimab is listed in the supplied FDA record under the brand name Imaavy and the name nipocalimab-aahu. The data identify the product’s class as Type 1 - New Molecular Entity. The supplied record does not provide a mechanism of action, therapeutic class, approved indication, dosing information, patient population, or prior approval history.
Approval details
The event was an initial FDA approval associated with biologics license application BLA 761430. The application sponsor was Janssen Biotech. The FDA record’s headline states that the agency approved Imaavy (nipocalimab-aahu).
The available data do not specify the disease or condition for which the product was approved, the approved population, the formulation, the route of administration, or the evidence supporting the decision. They also do not include clinical-trial enrollment, efficacy measurements, safety findings, statistical analyses, or labeling language.
What this means
The April 29, 2025 event establishes that the FDA granted an initial approval for Imaavy (nipocalimab-aahu) under BLA 761430. The classification as a Type 1 new molecular entity identifies the regulatory category supplied for this application.
Because the available data do not state an indication or population, they do not support describing which patients may receive Imaavy or what clinical benefit and risks the FDA evaluated. Those details require the agency’s full approval documentation or prescribing information.
Source
Source: U.S. Food and Drug Administration, biologics application overview record for BLA 761430, dated April 29, 2025. The record is available on the FDA’s accessdata.fda.gov website at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA761430.